IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs Transcript
Source: SeekingAlpha
2026-02-23 18:25:01 ET
IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs February 23, 2026 12:00 PM EST...
Read the full article on Seeking Alpha
For further details see:
IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs Transcript
IDEAYA Biosciences Inc.
NASDAQ: IDYA
IDYA Trading
0.49% G/L:
$34.96 Last:
186,017 Volume:
$35.27 Open:
IDYA Latest News
March 09, 2026 06:00:00 am
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deleted Solid Tumors, and Provides MTAP and CDKN2A Pipeline Update
February 25, 2026 06:00:00 am
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC
February 23, 2026 06:00:00 am
IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer
IDYA Stock Data
$2,916,661,394
85,474,748
1.71%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
